Obesity News

Semaglutide and tirzepatide confer greater improvements in life expectancy than naltrexone/bupropion and phentermine/topiramate, but their estimated net price is too high for them to be cost-effective, researchers reported.

Intentional weight loss of 5% or more, coupled with reduced waist circumference was associated with lower risk for death from cancer, CVD or any cause among postmenopausal women followed for more than 18 years, data show.

Adults with obesity and type 2 diabetes receiving once-weekly combination cagrilintide 2.4 mg and semaglutide 2.4 mg lost 15.7% of their body weight at 68 weeks, according to topline data from the REDEFINE 2 trial.

Adults with obesity who have a prescription for Wegovy but do not have insurance coverage for the drug can now purchase the medication through a new Novo Nordisk direct-to-consumer program.

Obesity prevalence increased among both adults and children across all regions of the world from 1990 to 2021, and more than half of adults are expected to have obesity by 2050, according to two reports published in The Lancet.

The increasingly popular obesity and diabetes drugs known as glucagon-like peptide-1 receptor agonists do not seem to worsen suicidality despite previous concerns, according to recent data published in BMJ.

The FDA recently removed semaglutide from its drug shortage list, which has not been considered commercially available since early 2022.

Adults with type 1 diabetes have greater reductions in body weight and HbA1c after using off-label semaglutide or tirzepatide than those not using either drug, according to data published in Diabetes Technology & Therapeutics.

Obesity trends have stayed stable in the last couple years, whereas severe obesity has trended downward, a recently published report suggested.